• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

After 40 investors rejected Jeff Bezos’ Amazon pitch, his parents offered $245,573 of their retirement savings

2

D.C.'s affordability headache has a silver bullet, new study shows: Tackling $40 trillion national debt would boost household income by $36,000

3

China now makes up a record 40% of all global container exports—and it’s a sign Trump’s tariffs meant to punish Chinese firms have fallen flat

1

After 40 investors rejected Jeff Bezos’ Amazon pitch, his parents offered $245,573 of their retirement savings

2

D.C.'s affordability headache has a silver bullet, new study shows: Tackling $40 trillion national debt would boost household income by $36,000

3

China now makes up a record 40% of all global container exports—and it’s a sign Trump’s tariffs meant to punish Chinese firms have fallen flat

Venture Capital deals

By
Dan Primack
Dan Primack
Down Arrow Button Icon
By
Dan Primack
Dan Primack
Down Arrow Button Icon
November 22, 2011, 3:37 PM ET
Google source logo
Add Fortune on Google for similar content.

Portola Pharmaceuticals, a South San Francisco-based drug company focused on cardiovascular and autoimmune/inflammatory diseases, has raised $89 million in new VC funding. New investors include Temasek, Eastern Capital and Biogen Idec ($9 million equity infusion as part of a strategic agreement that also includes a $45 million up-front cash payment). The company previously raised around $220 million from Abingworth Management, Advanced Technology Ventures, AllianceBernstein, Alta Partners, Brookside Capital, CIDC Consulting, D.E. Shaw, Frazier Healthcare Ventures, Goldman Sachs, IBT Management Corp., MPM  Capital, Prospect Venture Partners, Sutter Hill Ventures, Teachers’ Private Capital, T. Rowe Price, Apothecary Capital, Janus Capital and PAC-Link BioVentures. It also has strategic agreements with Merck & Co. and Novartis that could be worth more than $1 billion.www.portola.com

RunKeeper, a Boston-based social app for tracking exercise, has raised $10 million in second-round funding. Spark Capital led the round, and was joined by Revolution Ventures and return backer OATV.www.runkeeper.com

eVariant, a Simsbury, Conn.-based provider of SaaS-based CRM/PRM and marketing automation solutions for hospitals and healthcare organizations, has raised $5.3 million in first-round funding fromHealth Enterprise Partners. www.evariant.com

EyeSight Mobile Technologies, an Israel-based developer of touch-free interfaces for digital devices, has raised $4.2 million in Series B funding co-led by CEVA Inc. and Mitsui & Co. www.eyesight-tech.com

Power Assure Inc., a Santa Clara, Calif.-based provider of data center infrastructure and energy management solutions, has raised $1 million in strategic funding from Dominion Energy Technologies, an affiliate of Dominion Resources (NYSE: D). This closes out a $14.5 million Series B round that also includes ABB Technology Ventures, Good Energies, Point Judith Capital, and Draper Fisher Jurvetson.www.powerassure.com

ChanRx, a Cleveland-based developer of drugs to treat atrial fibrillation, has raised an undisclosed amount of Series A funding from Sante Ventures. www.chanrx.com

Get yesterday’s VC deals

About the Author
By Dan Primack
See full bioRight Arrow Button Icon

Latest in


Most Popular

Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    Latest in


    Most Popular

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.